Soleno Therapeutics Enters Material Definitive Agreement

Ticker: SLNO · Form: 8-K · Filed: 2025-07-11T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, filing, corporate-event

Related Tickers: SLNO

TL;DR

SOLENO THERAPEUTICS (SLNO) just signed a big deal, filing an 8-K today.

AI Summary

On July 10, 2025, Soleno Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. Soleno Therapeutics, Inc. is incorporated in Delaware and headquartered in Redwood City, CA.

Why It Matters

This filing indicates a significant new agreement for Soleno Therapeutics, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into material definitive agreements can introduce new risks related to contract terms, performance obligations, and potential liabilities.

Key Numbers

Key Players & Entities

FAQ

What type of material definitive agreement did Soleno Therapeutics, Inc. enter into?

The filing states that Soleno Therapeutics, Inc. entered into a 'Material Definitive Agreement' but does not specify the exact nature of the agreement in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on July 10, 2025.

Where is Soleno Therapeutics, Inc. headquartered?

Soleno Therapeutics, Inc.'s principal executive offices are located at 100 Marine Parkway, Suite 400, Redwood City, CA 94065.

What was Soleno Therapeutics, Inc. formerly known as?

Soleno Therapeutics, Inc. was formerly known as Capnia, Inc.

What is the SIC code for Soleno Therapeutics, Inc.?

The Standard Industrial Classification (SIC) code for Soleno Therapeutics, Inc. is 3845, which corresponds to Electromedical & Electrotherapeutic Apparatus.

From the Filing

0001193125-25-157728.txt : 20250711 0001193125-25-157728.hdr.sgml : 20250711 20250710214341 ACCESSION NUMBER: 0001193125-25-157728 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 20 CONFORMED PERIOD OF REPORT: 20250710 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250711 DATE AS OF CHANGE: 20250710 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC CENTRAL INDEX KEY: 0001484565 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 770523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36593 FILM NUMBER: 251117410 BUSINESS ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-213-8444 MAIL ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Capnia, Inc. DATE OF NAME CHANGE: 20100219 8-K 1 d52794d8k.htm 8-K 8-K SOLENO THERAPEUTICS INC false 0001484565 0001484565 2025-07-10 2025-07-10     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2025     SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)       Delaware   001-36593   77-0523891 (State or other jurisdiction of incorporation)   (Commission File No.)   (IRS Employer Identification Number) 100 Marine Parkway , Suite 400 Redwood City , CA 94065 (Address of principal executive offices) (650) 213-8444 (Registrant’s telephone number, including area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading symbols   Name of each exchange on which registered Common Stock, $0.001 par value   SLNO   NASDAQ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 1.01 Entry into a Material Definitive Agreement. Public Offering of Common Stock On July 10, 2025, Soleno Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named in Schedule I thereto (collectively, the “ Underwriters ”) relating to the issuance and sale in a public offering (the “ Public Offering ”) of an aggregate of 2,352,941 shares of the Company’s common stock, $0.001 par val

View on Read The Filing